Publications

Latest Publications

2023.04.21
How to Protect Assets in Relation to Digital Salary Payment - With regard to the Publication of Partial Revision of the "Guideline for Administrative Processes (Vol. 3: Financial Companies)" (Draft) (Dated February 17, 2023)
2023.04.20
How to win appellate cases where defense in the first instance is inadequate
2023.04.20
Latest Issues in Legal Practice to Cope with Shareholder Proposals
2023.04.10
The Private Equity Review 12th Edition : Japan - Investing
2023.04.05
[Series] Utilization of Business Transfer in Bankruptcy Cases (8th): Looking Back at the Series
2023.04.03
Avatarization of Celebrities and Contractual Practices in the Metaverse
2023.04.03
Trends in the Japanese Central Method for Offshore Wind Power
2023.04.03
Handling of Personal Data in the “Metaverse”
2023.03.31
150 Q&As on the Practice of Personal Insolvency Arrangements pursuant to the Guideline (Legal Practice Q&A Series of Zentoh Net)
2023.03.28
Response to the Risk of Misconduct in Business in China(2) - Facilitating Information Sharing with Chinese Subsidiaries
2023.03.28
Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
2023.03.28
[Report from China] Spring is the Season for Politics
2023.03
Legal Status of an Insurance Beneficiary under the Insurance Act: Changes to the Rule and Its Effects on Legal Interpretation
2023.03.24
High-Speed Trading Regulations in Japan – Latest Developments Almost Four Years after their Introduction –
2023.03.24
Compliance with Building Standards under the New Energy Regulations in Japan
2023.03.01
A Practical Commentary on the “Whistleblowing System” for Contact Persons at Reporting Desks - Practical Points in Operating the System and a Commentary on Cases -
2023.02.28
[Report from China] Chinese Courtroom TV Series – “Draw the Line”
2023.02.28
Response to the Risk of Misconduct in Business in China – Focusing on the Response to Signs of Misconduct
2023.02.28
Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
2023.02.28
A Commentary on the New Draft Amendment to the “Companies Law” of China – In Comparison with the First Draft Amendment

Other publications

ページTOPへ